Tysabri raises alarm bells on drug class

Article Abstract:

Tysabri, a first-in-class IgG4 monoclonal antibody that binds the alpha4 integrin, had prompted multibillion-dollar revenue forecasts on the strength of its potential as a treatment for multiple sclerosis and other autoimmune disorders, including Crohn's disease. The sudden withdrawal of Tysabri from the market has raised doubt on its future as a therapy for autoimmune disease and it also raises questions about the safety of all alpha4 integrin antagonists.

Product standards, safety, & recalls, Science & research, Research, Product defects and recalls, Causes of, Complications and side effects, Multiple sclerosis, Monoclonal antibodies, Demyelinating diseases, Tysabri (Medication)

---

Tysabri back on market

Article Abstract:

Investors have welcomed the return of Tysabri, a Multiple Sclerosis (MS) drug that was withdrawn from the US market in February 2005 after a suspected case of PML among patients who received it along with Avonex. The drug show blockbuster potential despite the safety concerns posed by it, for the multiple sclerosis market that is poorly served by the existing therapies.

Product introduction, Pharmaceutical Preparation Manufacturing, New Products/Services, Drugs, Central Nervous System Prep, United States, Biological products industry, Central nervous system agents, Elan Pharmaceuticals Inc.

---

Cimzia's setback paves way for other TNF inhibitors in Crohn's disease

Article Abstract:

The delay in an approval of Brussels-based UCB acquired drug Cimzia to treat Crohn's, an inflammatory bowel disease that commonly affects the small intestine allowed other firms to gain grounds in the lucrative and rapidly growing market fro TNF-[alpha] inhibitors.

Product development, Government regulation, Pharmaceutical industry, Licensing, certification and accreditation, Gastrointestinal agents, Antigas agents, UCB Pharma N.V./S.A.

Similar abstracts:

• Abstracts: V-22 Osprey program disputes 'out' call on icing incident. JSF production on track
• Abstracts: Boeing profits soar, but revenues slump on strike, DOD sales. Boeing, Armour Holdings finances soar on defense contracts
• Abstracts: Raytheon profit up 50 percent; Halliburton leads with 168.3 percent. Raytheon leads contractors as 2005 profits soar

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.